| pubmed-article:8436440 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8436440 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:8436440 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8436440 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:8436440 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:8436440 | lifeskim:mentions | umls-concept:C2266866 | lld:lifeskim |
| pubmed-article:8436440 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8436440 | pubmed:dateCreated | 1993-3-23 | lld:pubmed |
| pubmed-article:8436440 | pubmed:abstractText | Proteins can be detected by South-western analyses of human tumour-cell extracts binding to double-stranded oligonucleotide DNA treated in vitro with the chemotherapeutic drug cis-diamminedichloroplatinum (II) (CDDP), but not to untreated DNA. The relative molecular masses of proteins binding to the CDDP-treated double-stranded oligonucleotide are 25, 48 and 97 kDa. The binding activity of 2 of the CDDP-damage-recognition proteins, of relative molecular mass 48 and 97 kDa, is greater in a CDDP-resistant human ovarian tumour cell line than in the parental sensitive line. South-western analysis of a panel of human bladder cell lines and CDDP-sensitive testicular cell lines show consistent patterns of CDDP-damage-recognition proteins within each cell type, however with differences between the 2 cell types. Binding of the proteins to CDDP-damaged DNA and the altered binding activity detected in tumour cell lines suggests that alteration in damage-recognition proteins could play a role in tumour response to CDDP. | lld:pubmed |
| pubmed-article:8436440 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8436440 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8436440 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8436440 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8436440 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8436440 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8436440 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8436440 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8436440 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8436440 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8436440 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8436440 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:8436440 | pubmed:author | pubmed-author:BrownRR | lld:pubmed |
| pubmed-article:8436440 | pubmed:author | pubmed-author:MastersJJ | lld:pubmed |
| pubmed-article:8436440 | pubmed:author | pubmed-author:McLaughlinKK | lld:pubmed |
| pubmed-article:8436440 | pubmed:author | pubmed-author:CoreyRR | lld:pubmed |
| pubmed-article:8436440 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8436440 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:8436440 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:8436440 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8436440 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8436440 | pubmed:pagination | 662-6 | lld:pubmed |
| pubmed-article:8436440 | pubmed:dateRevised | 2007-7-24 | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:meshHeading | pubmed-meshheading:8436440-... | lld:pubmed |
| pubmed-article:8436440 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8436440 | pubmed:articleTitle | Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines. | lld:pubmed |
| pubmed-article:8436440 | pubmed:affiliation | CRC Department of Medical Oncology, Beatson Laboratories, Glasgow, UK. | lld:pubmed |
| pubmed-article:8436440 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8436440 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:8436440 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8436440 | lld:pubmed |
